The ability of this strategy to both re-identify known metastasis susceptibility genes (e.g., Cadm1) and validate novel tumor progression genes (e.g., Pvrl1, Zbtb16) is consistent with this hypothesis. This evidence concerns the gene NECTIN1 and neoplasm.